Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination

被引:20
作者
Brunner, Nathalie [1 ]
Bruggmann, Philip [1 ,2 ]
机构
[1] Swiss Hepatitis, Zurich, Switzerland
[2] Arud Ctr Addict Med, 31 Schutzengasse, CH-8001 Zurich, Switzerland
关键词
Hepatitis C; Policy; HIV; Awareness; Public health; VIRAL-HEPATITIS; VIRUS-INFECTION; TRANSMISSION; PREVALENCE; THERAPY; PEOPLE; BLOOD; RISK;
D O I
10.3961/jpmph.21.151
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis C infection is responsible for high morbidity and mortality rates globally as well as for significant indirect costs. The disease burden caused by the hepatitis C virus (HCV) is comparable to the one caused by human immunodeficiency virus or tuberculosis. Today, simple detection methods, highly effective and easy to administer therapies and efficient preventative measures are available to combat hepatitis C. Nevertheless, in most countries around the world, the World Health Organization target of eliminating this infectious disease and its consequences by 2030 are not being met. Significant gaps in care for hepatitis C sufferers still exist, the shortcomings ranging from education and treatment to aftercare. Hepatitis C infection was and still is not on the radar of most politicians and health authorities. National programmes and strategies to combat the disease exist or are being developed in many countries. However, for these to be implemented efficiently and successfully, clear political commitment, strong civil society actors, well-functioning public health structures and the relevant support from global donors are needed.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 50 条
  • [1] [Anonymous], 2013, The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C Epidemic
  • [2] [Anonymous], 2018, Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries
  • [3] [Anonymous], 2018, Fifth national hepatitis C strategy: 2018-2022
  • [4] [Anonymous], 2021, WORLD DRUG REP
  • [5] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
    Armstrong, Gregory L.
    Wasley, Annemarie
    Simard, Edgar P.
    McQuillan, Geraldine M.
    Kuhnert, Wendi L.
    Alter, Miriam J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) : 705 - 714
  • [6] Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
    Blach, Sarah
    Zeuzem, Stefan
    Manns, Michael
    Altraif, Ibrahim
    Duberg, Ann-Sofi
    Muljono, David H.
    Waked, Imam
    Alavian, Seyed M.
    Lee, Mei-Hsuan
    Negro, Francesco
    Abaalkhail, Faisal
    Abdou, Ahmed
    Abdulla, Maheeba
    Abou Rached, Antoine
    Aho, Inka
    Akarca, Ulus
    Al Ghazzawi, Imad
    Al Kaabi, Saad
    Al Lawati, Faryal
    Al Namaani, Khalid
    Al Serkal, Youssif
    Al-Busafi, Said A.
    Al-Dabal, Layla
    Aleman, Soo
    Alghamdi, Abdullah S.
    Aljumah, Abdulrahman A.
    Al-Romaihi, Hamad E.
    Andersson, Monique I.
    Arendt, Vic
    Arkkila, Perttu
    Assiri, Abdullah M.
    Baatarkhuu, Oidov
    Bane, Abate
    Ben-Ari, Ziv
    Bergin, Colm
    Bessone, Fernando
    Bihl, Florian
    Bizri, Abdul R.
    Blachier, Martin
    Blasco, Antonio J.
    Mello, Carlos E. Brandao
    Bruggmann, Philip
    Brunton, Cheryl R.
    Calinas, Filipe
    Chan, Henry L. Y.
    Chaudhry, Asad
    Cheinquer, Hugo
    Chen, Chien-Jen
    Chien, Rong-Nan
    Choi, Moon Seok
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 161 - 176
  • [7] The Swiss Hepatitis Strategy as a model for facing future health policy challenges
    Blindenbacher, Raoul
    Maeschli, Bettina
    Bruggmann, Philip
    [J]. HEALTH POLICY, 2019, 123 (07) : 681 - 687
  • [8] Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe
    Cacoub, P.
    Buggisch, P.
    Carrion, J. A.
    Cooke, G. S.
    Zignego, A. L.
    Beckerman, R.
    Younossi, Z.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2018, 25 (07) : 811 - 817
  • [9] Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
    Chhatwal, Jagpreet
    He, Tianhua
    Lopez-Olivo, Maria A.
    [J]. PHARMACOECONOMICS, 2016, 34 (06) : 551 - 567
  • [10] Assessing the cost-effectiveness of hepatitis C screening strategies in France
    Deuffic-Burban, Sylvie
    Huneau, Alexandre
    Verleene, Adeline
    Brouard, Cecile
    Pillonel, Josiane
    Le Strat, Yann
    Cossais, Sabrina
    Roudot-Thoraval, Francoise
    Canvas, Valerie
    Mathurin, Philippe
    Dhumeaux, Daniel
    Yazdanpanah, Yazdan
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 785 - 792